ATRC News and Press, AtriCure Inc. From 10/13/20

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a con...

Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction consider...

Among other criticisms, Kerrisdale Capital cites valuation as part of its short thesis on Atricure (ATRC), given it's near the "highest valuation in its history."Investors' assumptions on a "widespread adoption" of the Convergent procedure and growth in surgical devices are "misplaced."Shares...

AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedures. The TAM for AtriCure's core surgical ablation products is much smaller than AtriC...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference being held virtually...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory r...

For Q2 , ( ATRC -6.4% ) reported worldwide revenue of $40.8M (-30.7% Y/Y), beating consensus by $4.73M, as U.S. and International revenue dropped 28.6% and 39% respectively. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Stocks on the move, ...

Image source: The Motley Fool. AtriCure Inc   (NASDAQ: ATRC) Q2 2020 Earnings Call Jul 28, 2020 , 4:30 p.m. ET Operator Continue reading

AtriCure, Inc. (ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M. ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer...